Crystal structures of highly specific phosphinic tripeptide enantiomers in complex with the angiotensin-I converting enzyme

被引:26
作者
Masuyer, Geoffrey [1 ]
Akif, Mohd [1 ]
Czarny, Bertrand [2 ]
Beau, Fabrice [2 ]
Schwager, Sylva L. U. [3 ]
Sturrock, Edward D. [3 ]
Isaac, R. Elwyn [4 ]
Dive, Vincent [2 ]
Acharya, K. Ravi [1 ]
机构
[1] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England
[2] CEA, iBiTecS, Serv Ingn Mol Prot, Gif Sur Yvette, France
[3] Univ Cape Town, Inst Infect Dis & Mol Med, Div Med Biochem, ZA-7700 Rondebosch, South Africa
[4] Univ Leeds, Sch Biol, Leeds LS2 9JT, W Yorkshire, England
基金
英国惠康基金; 英国医学研究理事会;
关键词
angiotensin-I converting enzyme (ACE); Drosophila melanogaster; inhibitor binding; stereochemistry; X-ray crystallography; zinc metallopeptidase; 2; ACTIVE-SITES; ASP-LYS-PRO; C-DOMAIN; N-DOMAIN; SELECTIVE INHIBITOR; PEPTIDE; ACE; GLYCOSYLATION; NEPRILYSIN; BRADYKININ;
D O I
10.1111/febs.12660
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human somatic angiotensin-I converting enzyme (ACE) is a zinc-dependent dipeptidyl carboxypeptidase and a central component of the renin angiotensin aldosterone system (RAAS). Its involvement in the modulation of physiological actions of peptide hormones has positioned ACE as an important therapeutic target for the treatment of hypertension and cardiovascular disorders. Here, we report the crystal structures of the two catalytic domains of human ACE (N- and C-) in complex with FI, the S enantiomer of the phosphinic ACE/ECE-1 (endothelin converting enzyme) dual inhibitor FII, to a resolution of 1.91 and 1.85 angstrom, respectively. In addition, we have determined the structure of AnCE (an ACE homologue from Drosophila melanogaster) in complex with both isomers. The inhibitor FI (S configuration) can adapt to the active site of ACE catalytic domains and shows key differences in its binding mechanism mostly through the reorientation of the isoxazole phenyl side group at the P-1' position compared with FII (R configuration). Differences in binding are also observed between FI and FII in complex with AnCE. Thus, the new structures of the ACE-inhibitor complexes presented here provide useful information for further exploration of ACE inhibitor pharmacophores involving phosphinic peptides and illustrate the role of chirality in enhancing drug specificity.
引用
收藏
页码:943 / 956
页数:14
相关论文
共 61 条
[11]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[12]   Functional conservation of the active sites of human and Drosophila angiotensin I-converting enzyme [J].
Coates, D ;
Isaac, RE ;
Cotton, J ;
Siviter, R ;
Williams, TA ;
Shirras, A ;
Corvol, P ;
Dive, V .
BIOCHEMISTRY, 2000, 39 (30) :8963-8969
[13]   The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380 [J].
Corradi, Hazel R. ;
Chitapi, Itai ;
Sewell, B. Trevor ;
Georgiadis, Dimitris ;
Dive, Vincent ;
Sturrock, Edward D. ;
Acharya, K. Ravi .
BIOCHEMISTRY, 2007, 46 (18) :5473-5478
[14]   DESIGN OF POTENT COMPETITIVE INHIBITORS OF ANGIOTENSIN-CONVERTING ENZYME - CARBOXYALKANOYL AND MERCAPTOALKANOYL AMINO-ACIDS [J].
CUSHMAN, DW ;
CHEUNG, HS ;
SABO, EF ;
ONDETTI, MA .
BIOCHEMISTRY, 1977, 16 (25) :5484-5491
[15]   Differences in the hydrolysis of enkephalin congeners by the two domains of angiotensin converting enzyme [J].
Deddish, PA ;
Jackman, HL ;
Skidgel, RA ;
Erdos, EG .
BIOCHEMICAL PHARMACOLOGY, 1997, 53 (10) :1459-1463
[16]   N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme angiotensin-(1-7) and Keto-ACE [J].
Deddish, PA ;
Marcic, B ;
Jackman, HL ;
Wang, HZ ;
Skidgel, RA ;
Erdös, EG .
HYPERTENSION, 1998, 31 (04) :912-917
[17]   Phosphinic peptides as zinc metalloproteinase inhibitors [J].
Dive, V ;
Georgiadis, D ;
Matziari, M ;
Makaritis, A ;
Beau, F ;
Cuniasse, P ;
Yiotakis, A .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2004, 61 (16) :2010-2019
[18]   RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites [J].
Dive, V ;
Cotton, J ;
Yiotakis, A ;
Michaud, A ;
Vassiliou, S ;
Jiracek, J ;
Vazeux, G ;
Chauvet, MT ;
Cuniasse, P ;
Corvol, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4330-4335
[19]   Inhibition of Zinc Metallopeptidases in Cardiovascular Disease - From Unity to Trinity, or Duality? [J].
Dive, Vincent ;
Chang, Cheng-Fu ;
Yiotakis, Athanasios ;
Sturrock, Edward D. .
CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (31) :3606-3621
[20]   Safety issues associated with the use of angiotensin-converting enzyme inhibitors [J].
Ehlers, Mario R. .
EXPERT OPINION ON DRUG SAFETY, 2006, 5 (06) :739-740